1. The Vertex Pharmaceuticals for cancer treatments.

2. An independent cancer drug company, like a focused oncology division of Merck.

• BB-2124: An investigational PI3Ka inhibitor designed to target solid tumors with PIK3CA mutations.
• BBP-398: An investigational SHP2 inhibitor being developed for the treatment of various solid tumors, including those with KRAS mutations.
• BBP-454: A preclinical investigational SMAD4 modulator targeting SMAD4-deficient cancers.
• BBP-673: A preclinical investigational MEK inhibitor aimed at treating tumors with specific MAPK pathway alterations.

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biotechnology company focused on developing therapies for various cancers. As a clinical-stage company, BBOT does not currently have any commercialized products available on the market.

Therefore, BBOT does not have major customers in the traditional sense of selling products to other companies or directly to individuals. Their primary focus is on research and development, conducting clinical trials, and advancing their pipeline of oncology drug candidates.

Should any of their drug candidates receive regulatory approval in the future, BBOT would then establish commercialization strategies. These strategies typically involve selling to entities such as pharmaceutical distributors, hospitals, and pharmacies, or through licensing and partnership agreements with larger pharmaceutical companies for product distribution and sales.

• Lonza Group Ltd. (LONN)
• WuXi AppTec Co., Ltd. (WXJ)

Eli Wallace, PhD Chief Executive Officer

Eli Wallace serves as the Chief Executive Officer of BridgeBio Oncology Therapeutics, a position he has held since May 2024. Prior to this, he was the Chief Executive Officer of Oncology R&D and Chief Scientific Officer In Residence at BridgeBio from December 2019 to April 2024. Dr. Wallace's career also includes a significant tenure as Chief Scientific Officer at Peloton Therapeutics, where he was instrumental in the discovery and development of Welireg, a first-in-class HIF2α inhibitor. He also served as Director of Medicinal Chemistry at Array BioPharma, leading numerous research projects that resulted in eight new chemical entities entering human clinical trials for cancer treatment, including the approved drugs Mektovi, Tukya, and Koselugo.

Uneek Mehra, MBA, MMS Chief Financial Officer

Uneek Mehra holds the role of Chief Financial Officer at BridgeBio Oncology Therapeutics. No further specific background information related to founding or managing other companies, company sales, or a pattern of private equity-backed management roles was immediately available for Mr. Mehra in the provided search results.

Pedro J. Beltran, PhD Chief Scientific Officer

Pedro J. Beltran is the Chief Scientific Officer of BridgeBio Oncology Therapeutics. He was announced in this role in May 2024, alongside Eli Wallace's appointment as CEO, to lead the company's efforts in accelerating its novel precision oncology pipeline.

Yong (Ben) Ben, MD, MBA Chief Medical and Development Officer

Yong (Ben) Ben was appointed as Chief Medical and Development Officer of BridgeBio Oncology Therapeutics in September 2024. Dr. Ben brings over 25 years of experience in oncology drug development, having been instrumental in the approval of more than 10 molecules across over 20 indications. His prior roles include Venture Partner at Eight Roads Venture, acting Chief Executive Officer of AlphaGen, Chief Medical Officer at BeiGene from 2019 to 2022, and Chief Medical Officer at BioAtla from 2017 to 2019. He also served as the Global Clinical Leader of Immuno-Oncology Clinical Development at AstraZeneca.

Idan Elmelech, MA, MBA Senior Vice President, Strategy & Business Development

Idan Elmelech serves as the Senior Vice President of Strategy & Business Development for BridgeBio Oncology Therapeutics.

Intense and advanced competition in the SHP2 inhibitor space, with numerous larger pharmaceutical companies (e.g., Revolution Medicines, Novartis, Sanofi, AstraZeneca, Merck) actively developing their own SHP2 inhibitors. If a competitor successfully brings a SHP2 inhibitor to market with superior efficacy, safety, or speed, it could establish the standard of care and severely diminish the market opportunity for BridgeBio Oncology Therapeutics' BBP-925 program.

BridgeBio Oncology Therapeutics (BBOT) is developing a pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. The addressable markets for their main product candidates are substantial across several oncology indications.

Main Product Candidates and Addressable Markets:

• BBO-8520 (KRAS^G12C inhibitor): This drug targets KRAS^G12C mutant non-small cell lung cancer (NSCLC).
  • The global KRAS inhibitor market, which includes KRAS^G12C inhibitors, was valued at approximately USD 476 million in 2024 and is projected to reach USD 3,894 million by 2035, growing at a Compound Annual Growth Rate (CAGR) of 21%. North America is a dominant region in this market, anticipated to capture 78% of the overall market by 2035.
  • Another report estimates the global KRAS inhibitors market size at USD 112.71 million in 2024, growing to USD 118.26 million in 2025, and projected to surpass USD 182.36 million by 2034, with a CAGR of 4.93% between 2024 and 2034.
  • NSCLC currently dominates the KRAS market and is projected to account for 92% of the market share by 2035. Approximately 37% of NSCLC cases in the United States have the KRAS^G12C mutation. The non-small cell lung cancer (NSCLC) market as a whole was valued at approximately USD 32 billion in 2025 and is projected to grow at a CAGR of 8%.
• BBO-10203 (PI3Kα:RAS breaker): This candidate is being developed for HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer (CRC), and KRAS mutant non-small cell lung cancer (NSCLC).
  • The global phosphoinositide 3-kinase (PI3K) inhibitors market, relevant to BBO-10203, reached USD 1.38 billion in 2024 and is expected to grow to USD 1.56 billion in 2025, with a projected growth to USD 2.55 billion in 2029 at a CAGR of 13.2%. North America held the largest share in this market in 2024. The PI3K inhibitors market in the 7MM (United States, EU4, and Japan) is anticipated to grow significantly by 2034.
  • For HER2-positive breast cancer treatment, the global market was valued at USD 10.50 billion in 2021 and is expected to reach USD 11.83 billion by 2029, with a CAGR of 1.50%. Another report values the global HER2-targeted therapeutics market at USD 10.95 billion in 2025, forecasting it to reach USD 13.4 billion by 2030, with North America representing 41.91% of the revenue in 2024. The 7MM metastatic HER2-positive breast cancer market amounted to USD 2,711.6 million in 2024 and is expected to reach USD 3,108.1 million by 2035.
  • The 7MM metastatic HR+/HER2- breast cancer market was estimated to be nearly USD 9.1 billion in 2022, with anticipated positive growth by 2032. The HR+/HER2- breast cancer market is expected to register a CAGR of 9% from 2025 to 2031.
  • For KRAS mutant colorectal cancer, approximately 40% of CRC cases have KRAS mutations. There were about 66,000 cases of KRAS mutant colorectal cancer in the United States in 2024.
  • For KRAS mutant non-small cell lung cancer, refer to the market size information provided for BBO-8520 above.
• BBO-11818 (pan-KRAS inhibitor): This pan-KRAS inhibitor targets KRAS^G12D and KRAS^G12V mutants in solid tumors, including NSCLC, pancreatic ductal adenocarcinoma (PDAC), and CRC.
  • The global KRAS inhibitor market information, as detailed for BBO-8520, is also applicable here, with a global market size projected to reach USD 3,894 million by 2035.
  • For KRAS mutant colorectal cancer, approximately 40-50% of CRC cases have KRAS mutations, and in the United States, about 30% of CRC cases are KRAS^G12D.
  • For pancreatic ductal adenocarcinoma (PDAC), KRAS mutations appear in approximately 90% of cases. The 7 major pancreatic cancer market reached USD 2,386.9 million in 2024 and is expected to reach USD 9,033.0 million by 2035, exhibiting a CAGR of 12.88%. In the United States, approximately 42% of pancreatic cancer cases are KRAS^G12D.
  • For KRAS mutant non-small cell lung cancer, refer to the market size information provided for BBO-8520. Approximately 22-25% of NSCLC cases harbor KRAS mutations.

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company with its future revenue growth intrinsically linked to the successful advancement and potential commercialization of its precision oncology pipeline, as analysts currently forecast no revenue for the company in the immediate 2-3 year timeframe (2025-2027). The primary drivers of potential future revenue growth over the next two to three years stem from the progression of its novel small molecule therapeutics targeting RAS and PI3Kα pathway malignancies.

1. Advancement of BBO-8520 in KRAS^G12C Mutant Cancers: BBO-8520 is a direct inhibitor targeting both the "ON" and "OFF" states of KRAS^G12C, currently in a Phase 1 clinical trial (ONKORAS-101) for patients with KRAS^G12C mutant non-small cell lung cancer (NSCLC). Successful progression through clinical trials and demonstration of a differentiated efficacy and safety profile compared to existing therapies could pave the way for market approval and subsequent revenue generation.
2. Development of BBO-10203 as a RAS:PI3Kα Breaker: BBO-10203 is an orally bioavailable small molecule designed to inhibit the physical interaction between RAS and PI3Kα, aiming to inhibit RAS-driven PI3Kα-AKT signaling in tumors while avoiding hyperglycemia. BBOT anticipated filing an Investigational New Drug (IND) application for BBO-10203 in Q2 2024 and commencing patient enrollment later in the same year, subject to IND clearance. Positive clinical data from its early-stage development could establish its potential as a novel therapeutic option and a significant revenue driver.
3. Progression of BBO-11818, a PanKRAS Inhibitor: BBO-11818 is a pan-KRAS inhibitor targeting mutant KRAS in both its "ON" and "OFF" states. The company expected to file an IND for BBO-11818 in early 2025. As a pan-KRAS inhibitor, it has the potential to address a broader patient population beyond specific KRAS mutations like G12C, which, if successful in clinical development, could lead to a wider market opportunity and substantial revenue.
4. Expansion into New Indications and Patient Populations: As these pipeline assets advance, successful clinical data may support the expansion into additional cancer types or patient populations beyond the initial indications. For instance, BBO-8520 is also being evaluated in HER2+ breast cancer, HR+/HER2- breast cancer, and KRAS mutant colorectal cancer within the BREAKER-101 trial. Broadening the applicability of these therapies would naturally expand their potential market size and revenue generation.

Share Issuance

• BridgeBio Oncology Therapeutics completed a $450 million public offering through a combination with Helix Acquisition Corp. II.
• The company secured $200 million in private financing upon its launch.
• The company established a 2025 Stock Option and Incentive Plan and a 2025 Employee Stock Purchase Plan, which became effective upon closing, indicating ongoing issuance of securities to employees.

Inbound Investments

• BridgeBio Oncology Therapeutics received $200 million in private external capital.
• The company completed a $450 million public offering through a combination with Helix Acquisition Corp. II.

Capital Expenditures

• BridgeBio Oncology Therapeutics reported capital expenditures of $0.
• The primary focus of capital allocation is on advancing its pipeline of next-generation small molecule therapeutics for cancers driven by RAS and PI3Kα oncogenes.